Champoux Jennifer 4

What Happened
Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics (GLUE), exercised 2,176 stock options (cost $3.98/share) and immediately sold the 2,176 shares in an open‑market sale at $19.00/share. Exercise cost recorded: $8,660; gross sale proceeds: $41,344. The filing also shows the related disposition of the derivative instrument (the option) in the same transaction.

Key Details

• Transaction date: May 22, 2026
  • Exercise (M, acquired): 2,176 shares @ $3.98 = $8,660
  • Sale (S, disposed): 2,176 shares @ $19.00 = $41,344
  • Derivative disposition (M, disposed): 2,176 @ $0.00 (reflects conversion/exercise of the option)
• Footnotes:
  • F1: Transactions were made pursuant to a Rule 10b5‑1 trading plan adopted Feb 19, 2026.
  • F2: Option vesting: 25% vested May 28, 2025; remainder vests in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Filing timeliness: Form filed May 26, 2026 for a May 22, 2026 transaction; filing appears timely given the intervening federal holiday (Memorial Day).

Context
Because the shares were exercised and then sold the same day, this effectively looks like a cashless exercise where the shares were converted from options and immediately monetized. The sale was executed under a pre‑existing 10b5‑1 plan, which is a structured trading plan often used to avoid concerns about trading on material nonpublic information. This Form 4 is factual and does not indicate the insider’s personal motivations.